DB15803InvestigationalVaccines
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector... As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.
- Also known as
- Recombinant chimeric COVID-19 DC vaccine · Recombinant chimeric COVID-19 epitope DC vaccine;
- Code names
- Dendritic cells vaccine
What you can answer from here — as of April 23, 2025
Which companies are running trials of Dendritic cells vaccine, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account